Kelley designs nanostructured electrochemical biosensors -- including antifouling 'spiky' nanoelectrodes -- for amplification-free, point-of-care detection of nucleic acids and proteins (e.g. bacterial mRNA), aiming to replace slow, lab-based amplification assays with rapid electronic diagnostics deployable at the bedside.